AJANTA PHARMA LTD
Results for Q3 FY
2012-13
Q/E Dec, 2012
Ajanta
Pharma Has declared excellent
results for the third quarter ending Dec,2012.
Net Sales for Q3 FY 13 stands
at Rs.225.68 Cr; compared to Rs.183.68 Cr in Q2 FY 13 (+22.87%); and Rs.163.9
cr in Q3 FY 12 (+37.69%).The improvement in Sales is impressive.
Total
Expenditure for Q3 FY 13
stands at Rs.177.56 Cr; compared to
Rs.151.06 Cr in Q2 FY 13 (+17.54%); and Rs.138.32 cr in Q3 FY 12 (+28.37%). The
expenditure has grown less than proportionately compared to net Sales.
Profit
before Intt, Dep. & Taxes for Q3 FY 13 stands at Rs.48.12 Cr; compared to Rs.32.62 Cr in Q2 FY 13 (+47.52%);
and Rs.25.58 cr in Q3 FY 12 (+88.09%). Profit growth at this stage is very
impressive.
Net
Profit for Q3 FY 13 stands at Rs.32.57 Cr; compared to Rs.21.88 Cr in Q2
FY 13 (+48.86%); and Rs. 18.51 cr in
Q3 FY 12 (+75.98%). Net Profit Growth is excellent
Changes
in inventories of FGs,WIP, SIT for Q3 FY 13 stands at Rs(-)2.71 Cr; compared
to Rs(-)6.72 Cr in Q2 FY 13 ; and Rs(-)0.62.41 cr in Q3 FY 12.
Cost of
materials consumed for Q3 FY 13 stands at Rs.79.95 Cr; compared to Rs.60.40 Cr in Q2 FY 13 (+32.37%);
and Rs.50.62 cr in Q3 FY 12 (+57.94%).
Purchases
of SIT for Q3 FY 13 stands at Rs.8.00 Cr; compared to Rs.6.61 Cr
in Q2 FY 13 (+21.03%); and Rs.5.17 cr in Q3 FY 12 (+ 54.77%).
Employee expense for Q3 FY 13 stands at Rs.27.77 Cr; compared to
Rs.27.48 Cr in Q2 FY 13 (+1.06%); and Rs.20.05 cr in Q3 FY 12 (+ 38.48%).
Depreciation for Q3 FY 13
stands at Rs.8.06 Cr; compared to Rs.7.88 Cr in Q2 FY 13 (+2.28%); and Rs. 8.17 -1.31%).
Other
expenses for Q3 FY 13 stands at Rs.56.49 Cr; compared to Rs.55.41 Cr in Q2 FY
13 (+1.95%); and Rs.54.93 cr in Q3 FY 12 (+ 2.84%).
Profit
before tax for Q3 FY 13 stands at Rs.48.88Cr; compared to Rs.31.13 Cr in
Q2 FY 13 (+57.02%); and Rs.22.48 cr in Q3 FY 12 (+117.43%).
Tax
Expenses for Q3 FY 13 stands at Rs.16.31Cr; compared to Rs.9.25 Cr in Q2
FY 13 (+76.32%); and Rs.3.97 cr in Q3 FY 12 (+310.61%).
Face
Value of Share is Rs.5; Paid-up Equity stands at Rs.11.80
Cr
Basic EPS for Q3 FY 13
stands at Rs.13.91; compared to Rs.9.34 in Q2 FY 13; and Rs.15.81 in Q3 FY 12.
Diluted
EPS for Q3 FY 13 stands at Rs.13.88; compared to Rs.9.32 in Q2 FY 13; and Rs.15.81 in Q3 FY 12.
Public
Shareholding in the company stands at 27.3%.
Current Market
Price : Rs.519
52 week
high/low price : 803.80/314.00
Exports contributed 69% of Net sales in the quarter;
HIGH LIGHTS OF 9 M PERFORMANCE (ENDED DEC,2012)
Revenue from operations at rs.590 cr – a Growth of 38%
YoY
EBITDA at Rs.139 Cr –a Growth of 73%YoY
Profit After Tax : Rs.74 cr – a growth of 73% YoY
Exports contributed 62% of nest sales in last 9 months.
Ajanta Pharma has received market authorization in UK for Sildenafil tablets 50 mg and 100 mg
.Expects to launch it in June 13 in UK.
Ajanta has leading Brands in the therapeutic segments
of ophthalmology, Dermatology, and cardiology.
Exports to more than 25 countries
For last 10 years – Company says – its Consolidated
performance is with –CAGR of 22% revenue
and 46% of Net profit
RESULTS TABLE
|
Ajanta Pharma
|
31-12-12
|
30-09-12
|
%Dif QoQ
|
30-06-12
|
31-03-12
|
31-12-11
|
%Dif YoY
|
|
Net Sales
|
22568
|
18368
|
22.87
|
17179
|
17268.22
|
16389.9
|
37.69
|
|
Total Expenditure
|
17756
|
15106
|
17.54
|
14474
|
14450.42
|
13831.55
|
28.37
|
|
Profit before Intt, Dep.
& Taxes
|
4812
|
3262
|
47.52
|
2705
|
2817.8
|
2558.35
|
88.09
|
|
Net Profit
|
3257
|
2188
|
48.86
|
1958
|
2359.79
|
1850.83
|
75.98
|
|
Diluted EPS
|
13.88
|
9.32
|
48.93
|
16.68
|
20.11
|
15.81
|
-12.21
|
|
Changes in inventories of
FGs,WIP, SIT
|
-271
|
-672
|
-59.67
|
1548
|
-1884.12
|
-62.41
|
334.23
|
|
Cost of materials
consumed
|
7995
|
6040
|
32.37
|
4438
|
7801.08
|
5061.91
|
57.94
|
|
Purchases of SIT
|
800
|
661
|
21.03
|
528
|
602.34
|
516.89
|
54.77
|
|
Employee expense
|
2777
|
2748
|
1.06
|
2563
|
2489.06
|
2005.36
|
38.48
|
|
Depreciation
|
806
|
788
|
2.28
|
778
|
824.3
|
816.69
|
-1.31
|
|
Other expenses
|
5649
|
5541
|
1.95
|
4619
|
4617.76
|
5493.11
|
2.84
|
|
Total expenses
|
17756
|
15106
|
17.54
|
14474
|
14450.42
|
13831.55
|
28.37
|
|
Profit before tax
|
4888
|
3113
|
57.02
|
2312
|
3124.8
|
2248.04
|
117.43
|
|
Tax Expenses
|
1631
|
925
|
76.32
|
354
|
765.01
|
397.21
|
310.61
|
|
Face Value of Share (Rs )
|
5
|
5
|
0
|
10
|
10
|
10
|
-50
|
|
Paid-up Equity
|
1180
|
1180
|
0
|
1180
|
1179.61
|
1179.61
|
0.03
|
|
Basic EPS
|
13.91
|
9.34
|
48.93
|
16.72
|
20.15
|
15.81
|
-12.02
|
|
Diluted EPS
|
13.88
|
9.32
|
48.93
|
16.68
|
20.11
|
15.81
|
-12.21
|
|
Public Shareholding (%)
|
27.3
|
27.3
|
0
|
28.16
|
20.11
|
31.08
|
-12.16
|
*
* * E
N D *
* *
No comments:
Post a Comment